(Reuters Health) - Seniors who get new lenses implanted during cataract surgery may not only see better but also experience better sleep, suggests a new study of how light entering the eye regulates ...

Please provide your email address to receive an email when new articles are posted on . Omeros Corp. announced that the U.S. Food and Drug Administration has approved the use of phenylephrine and ...

Company to Host Conference Call Today at 9:00 a.m. EDT-- SEATTLE, March 13, 2012 /PRNewswire via COMTEX/ -- Omeros Corporation today reported positive data from its Phase 3 clinical trial evaluating ...

Omeros reported positive data from its Phase 3 clinical trial evaluating OMS302 in patients undergoing intraocular lens replacement surgery. OMS302 met its primary endpoint by demonstrating ...

SEATTLE, June 2, 2014--Omeros Corporation OMER +8.64% today announced that the U.S. Food and Drug Administration (FDA) has approved Omidria™ (phenylephrine and ketorolac injection) 1%/0.3% for use ...

Intraocular lenses (IOLs), implanted in the eye as treatment for cataracts or myopia, are a growing global market in an ageing population, one estimated to be worth more than $4.5 billion by 2022.

Johnson & Johnson announced today that it is expanding its portfolio of presbyopia-correcting intraocular lenses (PC-IOL) with the roll-out of TECNIS Odyssey IOL in India. The new full visual range ...

SEATTLE, Jan. 22, 2013 /PRNewswire/ – Omeros Corporation (OMER) today announced the successful completion of the 90-day safety database lock in the second of the Company's two pivotal Phase 3 clinical ...

Omeros reported positive data from the second of its two pivotal Phase 3 clinical trials evaluating OMS302 in patients undergoing intraocular lens replacement surgery. This multicenter, double-blind, ...

The US Food and Drug Administration (FDA) has approved phenylephrine and ketorolac injection (Omidria, Omeros Corporation) 1%/3% for use during cataract surgery or intraocular lens replacement (ILR), ...